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Objective: To determine the epidemiology and characterize the treatment prescribed for
severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Methods: Observational, retrospective study made through review of medical records of
Spanish patients aged ≥6 years. Patients diagnosed with severe AD who required care between
2013 and 2017 were included. The study groups were: 6–12 years; 13–18 years; and > 18 years.
Patients were followed for 5 years. The main measurements were the prevalence of AD,
comorbidity and treatment duration. Statistical signiﬁcance was established as p <0.05.
Results: We included 2323 patients with severe AD. The overall prevalence was 0.10% (95%
CI: 0.09–0.11%) and was 0.39%, 0.23% and 0.07% in the 6–12 years, 13–18 years and >18 years
age groups, respectively (p <0.001), the percentage of males was 58%, 48.6% and 39%,
respectively, and general comorbidity was 0.1, 0.2 and 0.9 points, respectively (p <0.001).The
most frequent comorbidities were asthma in 49.0%, 44.9% and 20.8%, respectively (p <0.001),
and anxiety in 79.7%, 65.8% and 67.3%, respectively (p <0.001). Oral corticosteroids were
administered in 97.3%, 90.9% and 81.7%, respectively (concomitant-medication). Cyclosporine
(45.3%), azathioprine (15.9%) and methotrexate (9.0%) were the most frequently prescribed
drugs; biologic agents were administered in 5.8% of patients (for AD).
Conclusion: In AD the presence of comorbidities was signiﬁcant, especially in the psycho-
logical, immunoallergic and cardiovascular areas. Cyclosporine was the most widely used
immunosuppressant. There was a degree of variability in the use and duration of the
treatments prescribed.
Keywords: severe atopic dermatitis, epidemiology, comorbidity, treatment, immunosuppressants,
biologics
Introduction
Atopic dermatitis (AD) is a recurrent chronic inﬂammatory skin disease.1 It is pruritic,
and the morphological expression varies with age, although there is a predominance of
recurrent eczematous forms.2 The aetiology is unknown but involves genetic factors
and a combination of allergic and non-allergic-based immune factors, such as epider-
mal barrier dysfunction, and environmental trigger factors.1,2
The prevalence varies but may affect up to 10% of the general population, of whom
up to 15–30% have moderate/severe forms, that may affect up to 10–20% in children
and 1–5% in adults, especially in developed countries.3–5 Reports suggest that mild
infantile forms disappear after puberty in up to 75% of cases. The prevalence incidence
is higher in females, although in childhood there is a predominance of males.2
AD has a signiﬁcant economic impact and affects the quality of life and the
psychosocial wellbeing of patients and families, increasing the risk of food allergies,
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asthma, allergic rhinitis, other inﬂammatory autoimmune dis-
eases, andmental health disorders.6–8 Inﬂammatory ﬂares may
affect the entire skin and results in complications such as
dehydration, hypernatremia, and cutaneous and systemic
infection. Patients with a family history, a late onset, dissemi-
nated disease in childhood, females and patients in whom AD
is associated with other allergic pathologies, such as asthma
and rhinitis, have a worse prognosis. Adult AD is usually
severe.1,9 In the severe forms of AD, drugs are used systemi-
cally and, although there is a considerable variation in the
speciﬁc drug used, the clinical response is frequently insufﬁ-
cient, in addition to the burden of frequent adverse events.10,11
Topical corticosteroids are the cornerstone of pharma-
cological treatment.1,2 However, in moderate/severe cases,
a wide variety of medications is used, some of which do not
have an approved indication, including topical immunomo-
dulators (tacrolimus and pimecrolimus), oral corticoster-
oids, cyclosporine, azathioprine, mycophenolate mofetil,
methotrexate, cyclophosphamide, biologic agents (omali-
zumab, rituximab, etanercept, adalimumab, ustekinumab,
inﬂiximab, secukinumab), apremilast, intravenous immu-
noglobulins and/or interferon gamma. Current advances in
the long-term treatment of AD suggest that better symptom
management may have a greater impact on quality of life.
Prevention of the cardiovascular comorbidity associated
with severe forms of AD may result in increased longevity
and decreased mortality in patients with AD.12,13
Available population-based evidence on the prevalence
of severe AD is unclear and poorly documented, with only
a few case series reports from specialized care, mainly by
dermatologists, but with little evidence on the impact in
the population. In Spain, there are no population-based
studies. Nowadays, there is a growing need for naturalistic
studies, representative of the real clinical conditions of
health interventions that adequately reﬂect the impact on
these patients from a population-based perspective. The
objective of this study was to determine and characterize
the treatment prescribed for severe AD in Spanish children
and adults in usual clinical practice and quantify the pre-
valence of associated comorbidities.
Patients And Methods
Design And Study Population
An observational, multicentre, longitudinal retrospective study
was performed based on review of medical records (compu-
terized databases, with dissociated data) and complementary
databases from seven Spanish Regions. The sample analysed
was of 2.2million patients, with wide representativeness of the
Spanish population. The sample was obtained from health
databases of various Spanish centres (uniﬁed in the BIG-
PAC, Real Life Data dissociated database: http://www.
encepp.eu/encepp/search.htm). The population analysed was
mostly urban, with low-medium socioeconomic status, and
predominantly industrial.
Inclusion And Exclusion Criteria
Patients requesting care with regard to AD between 2013 and
2017 were included. For the recruitment period, the last
available date was considered the index date. Inclusion cri-
teria were: a) age ≥ 6 years, b) patients with a diagnosis of
AD of a least one year prior to the index date, c) patients
prescribed of any medication for AD (with veriﬁcation of the
dosage, the time interval and duration of each treatment
administered), d) patients receiving ≥ 2 prescriptions during
the follow-up period, e) patients who underwent regular
monitoring (≥ 2 health records in the computerized system,
including ≥ 1 dermatology unit visit. Exclusion criteria were:
a) subjects transferred out to other centres or regions or due to
change of address, b) permanently-institutionalized patients,
and c) patients with a history of seborrhoeic dermatitis,
contact dermatitis and/or fungal eczema.
Study Groups
Three age groups were differentiated: 6–12 years, 13–18
years, and > 18 years. Patients were followed retrospectively
for 5 years from the date of inclusion/index.
Description Of Severe Atopic Dermatitis
Records of patients with AD were obtained according to the
International Classiﬁcation of Diseases (ninth edition)
Clinical Modiﬁcation (ICD-9-CM; 691.8, 692.9, 706.8),
and/or ICD-10-CM (L20, L28, L85.3), which includes AD,
allergic dermatitis, allergic eczema, atopic eczema and atopic
neurodermatitis. The diagnosis of AD was made by the
reference dermatologist according to the Haniﬁn and Rajka
criteria.14 Severe AD was deﬁned by the following criteria:
a) the administration of immunosuppressive treatment, b) the
administration of biological treatment, and/or c) hospitaliza-
tion due to an AD ﬂare.
Sociodemographic And Comorbidity
Variables
The following variables were collected: age (continuous and
by ranges), sex, time since diagnosis, the history of
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hypertension, diabetes, dyslipidaemia, ischemic heart dis-
ease, cerebrovascular accident, heart/kidney failure, COPD,
bronchial asthma, allergic rhinitis, depressive syndrome,
anxiety or agitation, celiac disease, and the body mass
index (BMI, Kg/m2). As a summary variable of general
comorbidity, the Charlson comorbidity index15 was used as
an approximation to the severity of the patient, and the
number of chronic comorbidities. In addition, the comorbid-
ities of patients with severe ADwere compared with those of
the general population through pairing by age and sex.
Medication Administered
The medication (active ingredients and biological drugs) indi-
cated for the treatment of severe AD were obtained according
to theAnatomical Therapeutic Chemical Classiﬁcation System
(ATC).16 The information was obtained from the records of
pharmacological prescriptions of medicines and/or hospital
pharmacy services. The choice of drug was at the physician’s
discretion. The following medications were collected: a)
immunosuppressants (frequent use in AD): cyclosporine
(L04AD01), methotrexate (L04AX03), azathioprine
(L04AX01), mycophenolate mofetil (L04AA06), cyclopho-
sphamide (L01AA01); b) biological agents: omalizumab
(R03DX05), rituximab (L01XC*), inﬂiximab (L04AB02),
secukinumab (L04AC10), ustekinumab (L04AC05), tocilizu-
mab (L04AC07), mepolizumab (R03DX09); and c) other
medications (indication not approved): apremilast
(L04AA32), immunoglobulins (J06B*), interferon-gamma
(L03AB*), hydroxychloroquine (P01BA*), tofacitinib
(L04AA29) and baricitinib (L04AA37). Number of treatment
cycles of immunosuppressants and the duration of biological
therapy were recorded. Systemic corticosteroids (H02A*)
administered in patients with severe AD were quantiﬁed as
rescue treatment (concomitant-medication).
Epidemiology: Prevalence
The prevalence rate was calculated according to patients
diagnosed with AD by a dermatologist and prescribed of
immunosuppressant or biological agents and/or hospita-
lized (numerator), as a proportion of patients assigned to
primary healthcare centres (denominator). Standardization
of the results was not required, due to the similarity of the
demographic characteristics of the sample in comparison
with general Spanish population.
Conﬁdentiality Of Information
Data conﬁdentiality (anonymous and dissociated) was
respected according to the Spanish Organic Law on Data
Protection (Law 15/1999 of December 13). The study was
classiﬁed by the Spanish Agency for Medicines and Health
Products (EPA-OD), and was approved by the Clinical
Research Ethics Committee, International University of
Catalonia (Barcelona).
Statistical Analysis
A data validation was carried out to ensure the quality of the
results. Descriptive statistics were expressed as absolute and
relative frequencies. Qualitative data was presented in per-
centage and 95% conﬁdence intervals (CI). Data was
retrieved according to the total number of subjects with
non-missing records. Means and standard deviation (SD)
were used to describe quantitative data. A bivariate analysis
was made according to the distribution of data (chi-square
test or ANOVA). Comorbidities in patients with severe AD
were compared with those in the general population using
propensity score matching (pairing). The estimators were age
and sex. The tolerance of the model was 2, with sampling
with substitution and giving priority to exact matches (1:2).
Statistical signiﬁcance was established as p <0.05. The sta-
tistical analysis was performed using SPSSWIN v. 23.
Results
Of the 2.2 million patients aged ≥6 years assigned to the
centres, 62,849 received a diagnosis of AD (Table 1), of
which 2323 (3.69%) were severe. 28 patients were
excluded from the study (reasons: inclusion/exclusion cri-
teria, 8; missing data: 14; loss follow-up: 6). The overall
prevalence of severe AD, according to the deﬁned criteria,
was 0.10% (95% CI: 0.09–0.11%).The prevalence in the
different age groups was 0.39%, 0.23% and 0.07% in the
6–12 years (N = 600), 13–18 years (N = 244) and >18
years (N = 1479), respectively (p <0.001). In all age
groups asthma frequency was higher than in the general
population (49%, 44.9% and 20.8%, respectively,
p<0.001). Asthma severity (intermittent, mildly persistent,
moderately persistent and severely persistent) was 16.1%,
25.4%, 45.0% and 13.5%, respectively, in patients aged
6–12 years, 14.5%, 30.4%, 44.3% and 10.8%, respectively,
in those aged 13–18 years, and 12%, 36.7%, 42.8% and
8.5%, respectively, in patients aged > 18 years (p = 0.013).
Anxiety/agitation diagnosis was higher in severe atopic
patients than in general population in all age groups. In
adults, the most frequent comorbidities were dyslipidae-
mia (46.0%), hypertension (38.9%), obesity (27.7%), and
diabetes mellitus (14.9%), which were higher than in the
general population (Table 2).
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Cyclosporine (N = 1053, 45.3%), azathioprine (N = 370,
15.9%) and methotrexate (N = 209, 9.0%) were the most
frequently used drugs; biological agents were used by 5.8%
(in AD), Table 3. Cyclosporine (38.5%), immunoglobulins
(34.3%) and azathioprine (25.0%) were the most frequent in
patients aged 6–12 years; cyclosporine (45.5%), azathioprine
(20.9%) and immunoglobulins (18%) in patients aged 13–18
years; and cyclosporine (48.1%), methotrexate (13.5%) and
azathioprine (11.4%) in patients aged > 18 years. The most
frequently used biological agent was omalizumab (3.7% in
patients aged 13–18 years and 3.0% in those aged > 18 years).
Three or more treatment cycles were administered in 34.2%,
10.3% and 10.0% of patients, respectively (p <0.001).
Systemic corticosteroids were administered in 97.3%, 90.9%
Table 1 Prevalence Of Atopic Dermatitis According To Age Group
Age Groups 6–12 Years 13–18 Years > 18 Years p
Patients with severe AD 600 244 1479
Patients with AD 17,533 6841 38,475
General population 151,910 106,346 1,973,278
Estimated prevalence of AD, % 11.5% 6.4% 1.9% <0.001
95% CI 11.0–12.0% 5.8–7.0% 1.8–2.0%
Estimated prevalence of severe AD, % 0.39% 0.23% 0.07% <0.001
95% CI 0.23–0.54% 0.04–0.41% 0.06–0.08%
Note: p: statistical signiﬁcance.
Abbreviation: AD, atopic dermatitis.
Table 2 Baseline Characteristics And Comorbidities Of The Study Population And The General Population By Age Group
Age Groups 6–12 Years 13–18 Years > 18 Years
Comparison By PS Severe AD Population Severe AD Population Severe AD Population
Number of patients, PS 600 1200 244 488 1479 2958
Demographic characteristics
Mean age, years 9.1 (2.0) 9.0 (2.0) 14.8 (1.6) 14.9 (1.7) 51.4 (14.7) 50.9 (14.8)
Sex (male) 58% 57.7% 48.6% 48.1% 39.0% 39.8%
Time since diagnosis, years 8.6 (3.1) – 10.9 (3.9) – 27.6 (4.3) –
General comorbidity
Mean Charlson Index 0.1 (0.2) 0.1 (0.2) 0.2 (0.2) 0.2 (0.2) 0.9 (0.3) 0.8 (0.3)
Mean comorbidities 1.1 (0.9) 1.0 (0.8) 1.5 (0.9) 1.2 (0.8) 3.2 (2.2) 2.8 (2.2)
Speciﬁc comorbidity
Hypertension 0.5% 0.4% 0.4% 0.3% 38.9% 36.1%*
Mellitus diabetes 0.3% 0.4% 1.2% 1.0% 14.9% 11.5%‡
Dyslipidaemia 2.5% 2.0% 2.1% 2.9% 46.0% 44%‡
Obesity 19.5% 17.5% 19.8% 18.8% 27.7% 24.1%†
Ischemic heart disease 0.5% 0.4% 0.8% 0.6% 5.7% 4.0%
Cerebrovascular accident 0.2% 0.3% 1.2% 0.7% 7.4% 5.5%
Heart/kidney failure 0.0% 0.0% 0.0% 0.0% 7.4% 6.2%
COPD 0.0% 0.0% 0.0% 0.0% 10.9% 9.3%
Bronchial asthma 49.0% 18.6%‡ 44.9% 11.9%† 20.8% 6.5%‡
Allergic rhinitis 25.0% 19.4%* 22.2% 17.2% 22.9% 10.2%‡
Depressive syndrome 0.3% 0.3% 0.8% 0.5% 12.6% 10.3%*
Anxiety or agitation 79.7% 32.4%‡ 65.8% 20.8%† 67.3% 35.3%‡
Celiac disease 0.5% 0.2% 1.3% 0.7% 2.2% 1.1%†
Body mass index, Kg/m2 15.2 (2.3) 14.1 (2.5) 19.5 (3.1) 17.8 (3.2) 28.6 (3.2) 27.5 (3.2)†
Notes: Values expressed in percentages or mean (standard deviation). Statistical signiﬁcance: ‡p <0.001, †p <0.01, *p <0.05 in the pairwise comparison. PS, pairing by age and sex.
Abbreviations: AD, atopic dermatitis; PS, Propensity Score Matching; COPD, chronic obstructive pulmonary disease.
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and 81.7% of patients, respectively (p <0.001; concomitant-
medication). The mean number of cycles of systemic corticos-
teroids administered during the 5 years of follow-up was 7.5
(SD: 3.3), with a mean duration of 12.1 (SD: 3.8) days; 1.1%
of patients were hospitalized due to atopic dermatitis.
Table 4 shows the medication administered and the
duration of the cycles. The two most frequently used
immunosuppressants represented 61.2% of the consump-
tion. Cyclosporine was the most frequently used second-
line immunosuppressant. There were variations in the
duration of each cycle in each of the drugs administered.
Discussion
There is a lack of evidence on the prevalence of severe
AD, although some authors place it at around 5%17,18,20
We found a lower ﬁgure, which may be due to the method
of measurement. The severity of AD was classiﬁed
according to the treatment administered, instead of the
use of a clinical scale. The fact is that AD has a ﬂuctuating
course and the degree of severity is not substantially
modiﬁed over time in most patients, and the possible
classiﬁcation bias (depending on the treatment) may sub-
stantially disappear. In moderate/severe cases a wide vari-
ety of drugs are used in combination; therefore, these
results may reﬂect the type of systemic prescription used
in usual clinical practice of the most severe/recurrent
forms.
The results show a close association betweenAD and other
immunoallergic expressions such as asthma and rhinitis.
Patients with a late-onset, females, and patients with AD
associated with other allergic diseases (asthma and rhinitis)
have a worse prognosis.1,2 The percentage of patients with
allergic comorbidity (asthma and rhinitis) may have been
underdiagnosed compared with other reports.1,2 This might
be because the comorbidities of these patients are not always
included in the computerizedmedical record.We also found an
association betweenAD and anxiety in all age groups andwith
depression in adults, in line with other reports.1,19,21,22 It is
known that.10,19 Comparison of comorbidity in adult patients
with severe AD with that of the general population showed a
marked association with various metabolic/cardiovascular risk
factors, such as hypertension, diabetes, dyslipidaemia and
obesity. Although our results are similar to those of other
studies,23 more data is required to reinforce the consistency
of our results and identify associations between chronic severe
AD and cardiovascular risk, which reduces life
expectancy.24,25
In our study, after 5 years of follow up, all patients had
received at least two types of systemic treatments for the
treatment of AD, with a frequent need for several cycles of
immunosuppressive treatment due to recurrences.
Management of signs and symptoms of AD with immu-
nosuppressive agents has been widely described.26,27 Despite
the difﬁculty in making comparisons, our results are also
consistent with previous publications, agreeing that cyclos-
porine stands out as the most effective drug. However, the
treatments administered by physicians in our study were
short- or medium-term, showing a conservative attitude
despite the existing variability.
However, data on the efﬁcacy of systemic treatment and
the long-term safety of immunosuppressants are limited,
and further studies are needed to standardize and agree on
their use. Cyclosporine is the only ﬁrst-line immunosup-
pressant approved by the EMA for the systemic treatment of
AD.28,29 There is ample evidence on the lack of control of
Table 3 Medication Administered For Severe Atopic Dermatitis
According To Age Group
Age Groups 6–12
Years
13–18
Years
> 18
Years
p
Immunosuppressants
Cyclosporine 38.5% 45.5% 48.1% <0.001
Azathioprine 25.0% 20.9% 11.4% 0.001
Methotrexate 1.2% 0.8% 13.5% <0.001
Mycophenolate mofetil 0.5% 6.2% 9.6% <0.001
Cyclophosphamide 0.2% 2.5% 2.2% 0.003
Other medications*
Hydroxychloroquine 0.0% 1.2% 4.2% <0.001
Interferon 0.0% 0.0% 1.4% 0.002
Immunoglobulins 34.3% 18.0% 1.5% <0.001
Apremilast 0.0% 0.4% 1.3% 0.001
Biological agents
Omalizumab 0.3% 3.7% 3.0% <0.001
Rituximab 0.0% 0.0% 0.6% 0.001
Secukinumab 0.0% 0.4% 1.8% 0.001
Inﬂiximab 0.0% 0.4% 1.4% 0.007
Treatment cycles
Mean cycles 1.9 (0.9) 1.4 (0.7) 1.4 (0.7) <0.001
1 46.2% 73.3% 74.7%
2 19.7% 16.5% 15.3%
3+ 34.2% 10.3% 10.0% <0.001
Other variables
Systemic corticosteroids** 97.3% 90.9% 81.7% <0.001
Hospitalization 0.8% 1.0% 1.8% 0.040
Notes: Values expressed in percentages or means (standard deviation). p: statistical
signiﬁcance. *Indication not approved. **Concomitant-medication.
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AD with current treatments and the need for rescue
medication,6,30 which was conﬁrmed in our study by the
high use of concomitant systemic corticosteroids.
Recently, dupilumab, a biological agent, has been sug-
gested as a reference treatment for AD. The safety proﬁle
was more effective to conventional immunosuppressants
(cyclosporine or methotrexate). Dupilumab was approved
by the EMA in September 2017 for the treatment of adult
patients with moderate/severe AD not adequately con-
trolled with topical therapies or when these are not
advisable.31
It should be noted that the prevalence of AD (total and
severe) decreases according to the increase in the age of
the patients (temporary follow-up).32 Two studies pub-
lished in our country conclude that moderate to severe
AD requiring treatment with systemic immunosuppres-
sants has a low prevalence in adults and children; and
that more studies will be needed to determine the real
epidemiology of the disease. Our results are consistent
with these publications.33,34
The possible limitations of the study affect the categor-
ization of the disease and the possible aforementioned
classiﬁcation bias (treatment vs. scales), attributable to
the information system used. Therefore, the study shows
the usual limitations of retrospective studies, such as, for
example, disease underreporting and variability in the
physicians and patients, due to the observational design.
In this regard, the possible inaccuracy of the diagnostic
coding of moderate/severe AD and other comorbidities, or
the non-inclusion of variables that could inﬂuence the ﬁnal
results (socioeconomic level, evolution of the pharmaco-
logical dose prescribed, therapeutic adherence, pheno-
types, etc.) should also be considered as limitations.
Likewise, we did not detail the possible overlap of medi-
cations between ﬂares or maintenance phase due to difﬁ-
culties in their measurement. The main limitation is shown
in the evaluation method, the lack of measurement of
clinical effectiveness and/or the lack of measurement of
adverse reactions. Conversely, conducting the study in
children, adolescents and adults simultaneously, and the
large number of patients diagnosed with AD included, may
be considered as the strengths of the study.
This disease results in a substantial comorbidities burden,
including psychological and immunoallergic and, in adults,
metabolic/cardiovascular components. Management of
severe AD may become challenging, as many treatments
have not received approval for use in severe AD, and the
clinical control is inadequate, as shown by the high use of
systemic corticosteroids. These difﬁculties in the disease
control show the unmet medical need of these patients.
Cyclosporine is the most widely used immunosuppressant.
The treatment of AD in general and of severe AD in
particular may require more-personalized therapy depending
on the phenotype. At present, clinical trials of biological
agents that may revolutionize the evolution and treatment
of AD are ongoing. Further studies are needed to determine
the real effectiveness of many of these treatments. Moreover,
future studies will require cost-effectiveness analyses and
improved diagnostic and severity measurement tools. In
addition, coordination strategies between the different health
levels and effective prevention programs are necessary to
delay the progression to more advanced stages of AD and
reduce ﬂares.
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